- Home
- ELAB vs DRMA Comparison
ELAB vs DRMA Comparison
Compare ELAB & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- DRMA
- Stock Information
- Founded
- ELAB 2020
- DRMA 2014
- Country
- ELAB United States
- DRMA United States
- Employees
- ELAB N/A
- DRMA N/A
- Industry
- ELAB
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- DRMA Health Care
- Exchange
- ELAB Nasdaq
- DRMA Nasdaq
- Market Cap
- ELAB 3.2M
- DRMA 3.3M
- IPO Year
- ELAB 2023
- DRMA 2021
- Fundamental
- Price
- ELAB $6.05
- DRMA $4.44
- Analyst Decision
- ELAB
- DRMA Strong Buy
- Analyst Count
- ELAB 0
- DRMA 1
- Target Price
- ELAB N/A
- DRMA $10.00
- AVG Volume (30 Days)
- ELAB 45.0K
- DRMA 79.8K
- Earning Date
- ELAB 11-13-2025
- DRMA 11-12-2025
- Dividend Yield
- ELAB N/A
- DRMA N/A
- EPS Growth
- ELAB N/A
- DRMA N/A
- EPS
- ELAB N/A
- DRMA N/A
- Revenue
- ELAB N/A
- DRMA N/A
- Revenue This Year
- ELAB N/A
- DRMA N/A
- Revenue Next Year
- ELAB N/A
- DRMA N/A
- P/E Ratio
- ELAB N/A
- DRMA N/A
- Revenue Growth
- ELAB N/A
- DRMA N/A
- 52 Week Low
- ELAB $4.29
- DRMA $4.55
- 52 Week High
- ELAB $903.86
- DRMA $23.70
- Technical
- Relative Strength Index (RSI)
- ELAB 47.41
- DRMA 50.49
- Support Level
- ELAB $5.02
- DRMA $4.55
- Resistance Level
- ELAB $5.60
- DRMA $5.22
- Average True Range (ATR)
- ELAB 0.39
- DRMA 0.44
- MACD
- ELAB 0.07
- DRMA 0.02
- Stochastic Oscillator
- ELAB 31.97
- DRMA 58.04
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.